Systematic review and meta-analysis of randomized clinical trials appraising the impact of cilostazol after percutaneous coronary intervention.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  American Heart Journal

• Publication date

  2008-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.ahj.2007.12.024PMID 18513523
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Thiazolidinediones and Risk of Repeat Target Vessel Revascularization Following Percutaneous Coronary Intervention

  2007cited by this paper
• Angiographic analysis of pattern of late luminal loss in sirolimus- and paclitaxel-eluting stents.

  2007cited by this paper
• Effects of triple antiplatelet therapy (aspirin, clopidogrel, and cilostazol) on platelet aggregation and P-selectin expression in patients undergoing coronary artery stent implantation.

  2007cited by this paper
• Comparison of triple versus dual antiplatelet therapy after drug-eluting stent implantation (from the DECLARE-Long trial).

  2007cited by this paper
• Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents.

  2007cited by this paper
• Making sense of the recent meta-analytical confusion concerning the safety of drug-eluting stents.

  2007cited by this paper
• Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents.

  2007cited by this paper
• Is late luminal loss an accurate predictor of the clinical effectiveness of drug-eluting stents in the coronary arteries?

  2006cited by this paper
• A prospective randomized antiplatelet trial of cilostazol versus clopidogrel in patients with bare metal stent.

  2006cited by this paper
• Comparison of two methods to detect publication bias in meta-analysis.

  2006cited by this paper
• Coronary Stent Restenosis in Patients Treated With Cilostazol

  2005cited by this paper
• Comparison of cilostazol and clopidogrel after successful coronary stenting.

  2005cited by this paper
• [Effects of cilostazol on long-term clinical outcomes after coronary stenting].

  2005cited by this paper
• Adjusted indirect comparison of intracoronary drug-eluting stents: evidence from a metaanalysis of randomized bare-metal-stent-controlled trials.

  2005cited by this paper
• RACTS: A Prospective Randomized Antiplatelet Trial of Cilostazol Versus Ticlopidine in Patients Undergoing Coronary Stenting: Long-Term Clinical and Angiographic Outcome

  2005cited by this paper
• Randomized comparison of cilostazol vs ticlopidine for antiplatelet therapy after coronary stenting.

  2005cited by this paper
• Effects of antiplatelet agents on subacute thrombosis and restenosis after successful coronary stenting: a randomized comparison of ticlopidine and cilostazol.

  2004cited by this paper
• Cilostazol, clopidogrel or ticlopidine to prevent sub-acute stent thrombosis: a meta-analysis of randomized trials.

  2004cited by this paper
• Comparison of Cilostazol and Ticlopidine for One-Month Effectiveness and Safety after Elective Coronary Stenting

  2004cited by this paper
• Cilostazol inhibits leukocyte integrin Mac-1, leading to a potential reduction in restenosis after coronary stent implantation.

  2004cited by this paper
• Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication.

  2003cited by this paper
• Measuring inconsistency in meta-analyses

  2003cited by this paper
• Multidrug Hybrid Therapy including an Angiotensin Receptor Antagonist to Prevent Restenosis after Coronary Stenting (Preliminary Report)

  2002cited by this paper
• Randomized comparison of cilostazol versus ticlopidine hydrochloride for antiplatelet therapy after coronary stent implantation for prevention of late restenosis.

  2002cited by this paper
• Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication

  2002cited by this paper
• Comparison of ticlopidine and cilostazol for the prevention of restenosis after percutaneous transluminal coronary angioplasty.

  2001cited by this paper
• Effects of cilostazol on late lumen loss and repeat revascularization after Palmaz-Schatz coronary stent implantation.

  2001cited by this paper
• Cilostazol for Prevention of Thrombosis and Restenosis after Intracoronary Stenting

  2001cited by this paper
• Effects of cilostazol on angiographic restenosis after coronary stent placement.

  2000cited by this paper
• Impact of cilostazol on restenosis after percutaneous coronary balloon angioplasty.

  1999cited by this paper
• Cilostazol

  1999cited by this paper
• Usefulness of cilostazol versus ticlopidine in coronary artery stenting.

  1999cited by this paper
• Effects of probucol and cilostazol alone and in combination on frequency of poststenting restenosis.

  1998cited by this paper
• Impact of cilostazol on intimal proliferation after directional coronary atherectomy.

  1998cited by this paper
• Effects of cilostazol on late lumen loss after Palmaz-Schatz stent implantation.

  1998cited by this paper
• Use of cilostazol, a novel antiplatelet agent, in a post-Palmaz-Schatz stenting regimen.

  1997cited by this paper
• A randomized trial of aspirin versus cilostazol therapy after successful coronary stent implantation.

  1997cited by this paper
• Effect of cilostazol in preventing restenosis after percutaneous transluminal coronary angioplasty.

  1997cited by this paper
• Pharmacologic Treatment of Intimal Hyperplasia After Metallic Stent Placement in the Peripheral Arteries: An Experimental Study

  1995cited by this paper

• Aspirin plus clopidogrel versus cilostazol -based triple antiplatelet therapy in patients with ischemic heart disease undergoing PCI: a systematic review and meta-analysis of randomized controlled trials

  2025cites this paper
• Cilostazol alleviates imatinib-induced myocardial injury in rats by modulating the TGF-β1/MAPK, SHC/Grb2/SOS signaling pathways and upregulating miRNA-195-5P

  2025cites this paper
• Cilostazol-loaded acellular vascular graft for suppressing intimal hyperplasia.

  2025cites this paper
• Approaches for Increasing Cerebral Efflux of Amyloid-β in Experimental Systems

  2024cites this paper
• The Role of Cilostazol, a Phosphodiesterase-3 Inhibitor, in the Development of Atherosclerosis and Vascular Biology: A Review with Meta-Analysis

  2024cites this paper
• Inhibitory effect of cilostazol on intimal hyperplasia and smooth muscle cell proliferation in a rabbit carotid artery anastomosis model

  2023cites this paper
• The contemporary use of intracoronary brachytherapy for instent restenosis: A review.

  2023cites this paper
• Update on Cilostazol: A Critical Review of Its Antithrombotic and Cardiovascular Actions and Its Clinical Applications

  2021cites this paper
• Antiplatelet drugs overview

  2020cites this paper
• Therapeutic potential of phosphodiesterase inhibitors for endothelial dysfunction-related diseases.

  2020cites this paper
• Antiplatelet Therapy

  2020cites this paper
• Meta-analysis of Duration of Continuous Dual Antiplatelet Therapy and Late Stent Thrombosis After Second-Generation Drug Stent Implantation

  2020cites this paper
• Effect of cilostazol, a phosphodiesterase‐3 inhibitor, on coronary artery stenosis and plaque characteristics in patients with type 2 diabetes: ESCAPE study

  2019cites this paper
• Outcomes with cilostazol after endovascular therapy of peripheral artery disease

  2019cites this paper
• Prevention of atherothrombotic events in patients with diabetes mellitus: from antithrombotic therapies to new-generation glucose-lowering drugs

  2018cites this paper
• The effect of cilostazol, a phosphodiesterase 3 (PDE3) inhibitor, on human hair growth with the dual promoting mechanisms.

  2018cites this paper
• Randomized Angiographic and Intravascular Ultrasound Comparison of Dual-Antiplatelet Therapy vs Triple-Antiplatelet Therapy to Reduce Neointimal Tissue Proliferation in Diabetic Patients.

  2017cites this paper
• The efficacy and safety of cilostazol as an alternative to aspirin in Chinese patients with aspirin intolerance after coronary stent implantation: a combined clinical study and computational system pharmacology analysis

  2017cites this paper
• Restenosis after Coronary and Peripheral Intervention: Efficacy and Clinical Impact of Cilostazol.

  2017cites this paper
• Drug‐eluting stenting for femoropopliteal lesions, followed by cilostazol treatment, reduces stent restenosis in patients with symptomatic peripheral artery disease

  2017influential citation
• Commentary: Cilostazol and Carotid Stenting

  2016cites this paper
• Network Meta-analysis to Synthesize Evidence for Decision Making in Cardiovascular Research

  2016cites this paper
• Antiplatelet Effect of Sequential Administration of Cilostazol in Patients with Acetylsalycilic Acid Resistance.

  2016cites this paper
• THE SUCCESS OF DIFFERENT APPROACHES TO THE DEVELOPMENT TO ANTIPLATELET DRUGS

  2016cites this paper
• Triple versus dual antiplatelet therapy after percutaneous coronary intervention for coronary bifurcation lesions: results from the COBIS (COronary BIfurcation Stent) II Registry

  2015cites this paper
• Clinical Efficacy and Safety of Cilostazol: A Critical Review of the Literature

  2015cites this paper
• Retrograde recanalisation of popliteal artery occlusion Popliteal arter

  2015cites this paper
• Unexpected Discontinuation of Dual Antiplatelet Therapy within 14 Days after Percutaneous Coronary Intervention: A Single-center Case Series.

  2015cites this paper
• Network meta-analysis for evidence synthesis: what is it and why is it posed to dominate cardiovascular decision making?

  2015cites this paper
• Retrograde recanalisation of popliteal artery occlusion.

  2015cites this paper
• Effect of Antiplatelet Therapy on Coronary Heart Disease Risk in Patients

  2014influential citation
• Cilostazol eliminates adverse smoking outcome in patients with drug-eluting stent implantation.

  2014cites this paper
• Cilostazol increases patency and reduces adverse outcomes in percutaneous femoropopliteal revascularisation: a meta-analysis of randomised controlled trials

  2014cites this paper
• Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines

  2014cites this paper
• Cilostazol is associated with improved outcomes after peripheral endovascular interventions.

  2014cites this paper
• Antiplatelet Drugs in the Management of Cardiovascular Indications

  2014cites this paper
• Etude du rôle des étapes initiales d'adhérence des plaquettes sanguines et du flux pulsatile dans l'agrégation plaquettaire

  2014cites this paper
• A Critical Review of Meta-Analysis of Adverse Events After Contrast Media

  2014cites this paper
• Antiplatelet therapy in patients with diabetes mellitus and acute coronary syndrome.

  2014cites this paper
• Platelets and atherothrombosis: causes, targets and treatments for thrombosis.

  2013cites this paper
• Frequency‐domain optical coherence tomography assessment of unprotected left main coronary artery disease—a comparison with intravascular ultrasound

  2013cites this paper
• Addition of Cilostazol to Conventional Dual Antiplatelet Therapy Reduces the Risk of Cardiac Events and Restenosis After Drug‐Eluting Stent Implantation: A Meta‐Analysis

  2013cites this paper
• Triple versus dual antiplatelet therapy for coronary heart disease patients undergoing percutaneous coronary intervention: A meta-analysis

  2013cites this paper
• Effect of cilostazol addition or clopidogrel doubling on platelet function profiles in diabetic patients undergoing a percutaneous coronary intervention

  2013cites this paper
• Inflammatory mechanisms of adverse reactions to BMS.

  2013cites this paper
• Effect of tadalafil on neointimal hyperplasia in a rabbit carotid artery anastomosis model.

  2013cites this paper
• Comparison of On-Treatment Platelet Reactivity Between Triple Antiplatelet Therapy With Cilostazol and Standard Dual Antiplatelet Therapy in Patients Undergoing Coronary Interventions

  2013influential citation
• Efficacy and Safety of Adjunctive Cilostazol to Dual Antiplatelet Therapy After Stent Implantation

  2013cites this paper
• Effect of cilostazol for reduction of restenosis and intimal hyperplasia following carotid artery stenting: a multicenter analysis

  2013cites this paper
• The role of platelets in athero-thrombotic events.

  2012cites this paper
• Primary and secondary prevention of cardiovascular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

  2012cites this paper
• Cilostazol Prevents Progression of Asymptomatic Carotid Artery Stenosis in Patients with Contralateral Carotid Artery Stenting

  2012cites this paper
• Periprocedural cilostazol treatment and restenosis after carotid artery stenting: the Retrospective Study of In-Stent Restenosis after Carotid Artery Stenting (ReSISteR-CAS).

  2012cites this paper
• Challenges and perspectives of antiplatelet therapy in patients with diabetes mellitus and coronary artery disease.

  2012cites this paper
• Restenosis after stent implantation for superficial femoral artery disease in patients treated with cilostazol

  2012cites this paper
• Cilostazol and primary-PCI: mirage or good alternative?

  2012cites this paper
• Increased Atherothrombotic Burden in Patients with Diabetes Mellitus and Acute Coronary Syndrome: A Review of Antiplatelet Therapy

  2012cites this paper
• Meta-analysis of randomized controlled trials on effect of cilostazol on restenosis rates and outcomes after percutaneous coronary intervention.

  2012cites this paper
• A Meta-Analysis of Randomized Controlled Trials Appraising the Efficacy and Safety of Cilostazol after Coronary Artery Stent Implantation

  2012cites this paper
• Antiplatelet therapy in patients with diabetes mellitus.

  2012cites this paper
• Impact of cilostazol on angiographic restenosis after balloon angioplasty for infrapopliteal artery disease in patients with critical limb ischemia.

  2012cites this paper
• Antiplatelet drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

  2012cites this paper
• Evidence-Based Clinical Practice Guidelines American College of Chest Physicians and Prevention of Thrombosis, 9th ed: Antiplatelet Drugs : Antithrombotic Therapy

  2012cites this paper
• The long-term efficacy of cilostazol in addition to dual antiplatelet therapy after sirolimus-eluting stent implantation for Japanese patients: an analysis of the 3-year follow-up outcomes from the j-Cypher registry

  2012cites this paper
• ORIGINAL RESEARCH Cilostazol Prevents Progression of Asymptomatic Carotid Artery Stenosis in Patients with Contralateral Carotid Artery Stenting

  2012cites this paper
• Cilostazol-Based Triple Antiplatelet Therapy Compared to Dual Antiplatelet Therapy in Patients with Coronary Stent Implantation: A Meta-Analysis of 5,821 Patients

  2012cites this paper
• Sekundärprävention bei Patienten mit peripherer arterieller Verschlusskrankheit

  2011cites this paper
• New therapeutic approaches to combat arterial thrombosis: better drugs for old targets, novel targets, and future prospects.

  2011cites this paper
• Clopidogrel-Induced Neutropenia after Coronary Stenting: Is Cilostazol a Good Alternative?

  2011cites this paper
• Impact of Cilostazol on Left Ventricular Geometry and Function: Assessment by Tissue Doppler Imaging and Two‐Dimensional Speckle‐Tracking Echocardiography

  2011cites this paper
• Diabetes and Cardiovascular Disease Diabetes and Antiplatelet Therapy in Acute Coronary Syndrome

  2011cites this paper
• Percutaneous Coronary Intervention for Left Main and Multivessel Coronary Artery Disease – A Review of Strategies

  2011cites this paper
• Advances in antiplatelet therapy.

  2011cites this paper
• Diabetes and Antiplatelet Therapy in Acute Coronary Syndrome

  2011cites this paper
• Impact of cilostazol after endovascular treatment for infrainguinal disease in patients with critical limb ischemia.

  2011cites this paper
• Use of antiplatelet therapies during primary percutaneous coronary intervention for acute myocardial infarction

  2010cites this paper
• Oral antiplatelet therapy in patients with diabetes mellitus and acute coronary syndromes.

  2010cites this paper
• Intracranial stenting in atherosclerotic disease—recent results and challenges to face

  2010cites this paper
• Nuevos antiagregantes en el síndrome coronario agudo. El futuro es hoy

  2010cites this paper
• Inhibición del receptor plaquetario P2Y12 de adenosina difosfato plaquetario: efectos beneficiosos y limitaciones de las estrategias terapéuticas actuales y perspectivas futuras

  2010cites this paper
• Platelet adenosine diphosphate P2Y12 receptor antagonism: benefits and limitations of current treatment strategies and future directions.

  2010cites this paper
• Antiplatelet therapies for the treatment of cardiovascular disease

  2010cites this paper
• Systematic review and meta-analysis of outcomes after coronary revascularization procedures with regard to antiplatelet treatment and bleeding complications

  2010cites this paper
• Suppression of Neointimal Hyperplasia by External Application of Cilostazol-Eluting Film at Anastomotic Sites in a Canine Model

  2010cites this paper
• The treatment of clopidogrel resistance: triple antiplatelet therapy and future directions.

  2010cites this paper
• Alternatives to clopidogrel for acute coronary syndromes: Prasugrel or ticagrelor?

  2010cites this paper
• Silence of the limbs pharmacological symptomatic treatment of intermittent claudication.

  2010cites this paper
• Review article: Antithrombotic therapy in patients with diabetes mellitus and coronary artery disease

  2010cites this paper
• Percutaneous coronary intervention for small vessel coronary artery disease.

  2010cites this paper
• Transradial versus transfemoral percutaneous coronary intervention in acute myocardial infarction Systematic overview and meta-analysis.

  2009cites this paper
• Diabetes mellitus: a prothrombotic state Implications for outcomes after coronary revascularization

  2009cites this paper
• What is the optimum perioperative drug therapy following lower-extremity vein bypass surgery?

  2009cites this paper
• Novel antiplatelet therapies following percutaneous coronary interventions.

  2009cites this paper
• Retrograde transpedale recanalisation of tibial artery occlusion.

  2009cites this paper
• Polyvascular atherosclerotic disease: recognizing the risks and managing the syndrome

  2009cites this paper
• Combined aspirin and cilostazol treatment is associated with reduced platelet aggregation and prevention of exercise-induced platelet activation.

  2009cites this paper
• Stadiengerechte medikamentöse Therapie bei arterieller Verschlusskrankheit

  2009cites this paper
• Update on oral antiplatelet therapy: principles, problems and promises.

  2009cites this paper
• Efficacy of cilostazol in reducing restenosis in patients undergoing contemporary stent based PCI: a meta-analysis of randomised controlled trials.

  2009cites this paper
• Antiplatelet agents.

  2009cites this paper